Supporting evidence
Glimepiride × HbA1c
- Authoritative support
- 3
- Available studies
- 3
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Adding medications improves blood sugar control in diabetes patients.
Rct
- Comparison
- Participants received empagliflozin as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors. · Participants received pioglitazone as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors. · Participants received glimepiride as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors.
- Duration / follow-up
- 3900 weeks
Relevant effects
Mean difference
0.78
Mean difference
0.89
Mean difference
0.93
Study 2 · Included
Empagliflozin reduces body fluid volume in type 2 diabetes patients
Rct
- Comparison
- Patients received empagliflozin for 12 weeks after initial treatment. · Patients received glimepiride for 12 weeks after initial treatment.
- Duration / follow-up
- 136 weeks
Study 3 · Limited
Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.
Rct
- Comparison
- Patients received insulin glargine in the morning with fixed doses of metformin. · Patients received insulin glargine in the morning with fixed doses of glimepiride. · Patients received insulin glargine in the morning with fixed doses of both glimepiride and metformin.
- Duration / follow-up
- 24 weeks
Relevant effects
Mean difference
0.8 · 0.005
Mean difference
0.7 · 0.012
Mean difference
1.4 · 0.02